Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543041 | 0.86 | F10 (0.56) | F10L3MBTL3L3MBTL1KDM4CIRAK4 | |
| SCHEMBL3542891 | 0.81 | F10 (0.57) | F10L3MBTL3L3MBTL1IRAK4ACHE | |
| SCHEMBL31052605 | 0.78 | PKM (0.59) | SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL3539769 | 0.77 | F10 (0.74) | F10L3MBTL3L3MBTL1IRAK4F2 | |
| SCHEMBL3542890 | 0.77 | F10 (0.55) | F10L3MBTL3L3MBTL1IRAK4ACHE | |
| SCHEMBL8266530 | 0.74 | F10 (1.00) | F10L3MBTL3L3MBTL1IRAK4F2 | |
| SCHEMBL24802129 | 0.72 | ALDH1A1 (0.49) | F10L3MBTL3L3MBTL1ACHESMN1; SMN2 | |
| SCHEMBL4678853 | 0.72 | L3MBTL3 (0.50) | F10L3MBTL3L3MBTL1ACHEF2 | |
| SCHEMBL24204406 | 0.70 | ALDH1A1 (0.45) | F10L3MBTL3L3MBTL1ACHEF2 | |
| SCHEMBL13612604 | 0.70 | L3MBTL3 (0.51) | F10L3MBTL3L3MBTL1ACHEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | disclosed |
| EP-1846381-B1 | HETEROARYLACETAMIDES AS FACTOR Xa INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-7361672-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1846381-A2 | NOVEL HETEROARYLACETAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | US | disclosed |
| WO-2006066778-A2 | NOVEL HETEROARYLACETAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | F12, TFPI, F2 | F10 9/4885L3MBTL3 4756/4885L3MBTL1 4703/4885 |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F2, TFPI, F11 | F10 24/4885L3MBTL3 4553/4885L3MBTL1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.